These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22587749)

  • 21. Saccharomyces cerevisiae Gis2 interacts with the translation machinery and is orthogonal to myotonic dystrophy type 2 protein ZNF9.
    Sammons MA; Samir P; Link AJ
    Biochem Biophys Res Commun; 2011 Mar; 406(1):13-9. PubMed ID: 21277287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homozygosity for CCTG mutation in myotonic dystrophy type 2.
    Schoser BG; Kress W; Walter MC; Halliger-Keller B; Lochmüller H; Ricker K
    Brain; 2004 Aug; 127(Pt 8):1868-77. PubMed ID: 15231584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The myotonic dystrophies: molecular, clinical, and therapeutic challenges.
    Udd B; Krahe R
    Lancet Neurol; 2012 Oct; 11(10):891-905. PubMed ID: 22995693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and Validation of a New Molecular Diagnostic Assay for Detection of Myotonic Dystrophy Type 2.
    Valaperta R; Lombardi F; Cardani R; Fossati B; Brigonzi E; Merli I; Sansone V; Merletti G; Spina E; Meola G; Costa E
    Genet Test Mol Biomarkers; 2015 Dec; 19(12):703-9. PubMed ID: 26505324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of the innate immune response and interferon signalling in myotonic dystrophy type 1 and type 2 cataracts.
    Rhodes JD; Lott MC; Russell SL; Moulton V; Sanderson J; Wormstone IM; Broadway DC
    Hum Mol Genet; 2012 Feb; 21(4):852-62. PubMed ID: 22062891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Molecular and genetic aspects of the myotonic conditions].
    Morales Montero F; Cuenca Berger P
    Rev Neurol; 2004 Apr 1-15; 38(7):668-74. PubMed ID: 15098190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unusual clinical, laboratory, and muscle histopathological findings in a family with myotonic dystrophy type 2.
    Toth C; Dunham C; Suchowersky O; Parboosingh J; Brownell K
    Muscle Nerve; 2007 Feb; 35(2):259-64. PubMed ID: 17068784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-segregation of DM2 with a recessive CLCN1 mutation in juvenile onset of myotonic dystrophy type 2.
    Cardani R; Giagnacovo M; Botta A; Rinaldi F; Morgante A; Udd B; Raheem O; Penttilä S; Suominen T; Renna LV; Sansone V; Bugiardini E; Novelli G; Meola G
    J Neurol; 2012 Oct; 259(10):2090-9. PubMed ID: 22407275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CCUG repeats reduce the rate of global protein synthesis in myotonic dystrophy type 2.
    Schneider-Gold C; Timchenko LT
    Rev Neurosci; 2010; 21(1):19-28. PubMed ID: 20458885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical, electrophysiologic and pathologic findings in 10 patients with myotonic dystrophy 2.
    Dabby R; Sadeh M; Herman O; Leibou L; Kremer E; Mordechai S; Watemberg N; Frand J
    Isr Med Assoc J; 2011 Dec; 13(12):745-7. PubMed ID: 22332444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absent, unrecognized, and minimal myotonic discharges in myotonic dystrophy type 2.
    Young NP; Daube JR; Sorenson EJ; Milone M
    Muscle Nerve; 2010 Jun; 41(6):758-62. PubMed ID: 20513102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type 2 myotonic dystrophy can be predicted by the combination of type 2 muscle fiber central nucleation and scattered atrophy.
    Bassez G; Chapoy E; Bastuji-Garin S; Radvanyi-Hoffman H; Authier FJ; Pellissier JF; Eymard B; Gherardi RK
    J Neuropathol Exp Neurol; 2008 Apr; 67(4):319-25. PubMed ID: 18379436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PROMM and deafness: exclusion of ZNF9 as the disease gene in DFNA18 suggests a polygenic origin of the PROMM/DM2 phenotype.
    Bönsch D; Neumann C; Lang-Roth R; Witte O; Lamprecht-Dinnesen A; Deufel T
    Clin Genet; 2003 Jan; 63(1):73-5. PubMed ID: 12519376
    [No Abstract]   [Full Text] [Related]  

  • 34. Eosinophilic myositis as first manifestation in a patient with type 2 myotonic dystrophy CCTG expansion mutation and rheumatoid arthritis.
    Meyer A; Lannes B; Carapito R; Bahram S; Echaniz-Laguna A; Geny B; Sibilia J; Gottenberg JE
    Neuromuscul Disord; 2015 Feb; 25(2):149-52. PubMed ID: 25443993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myotonic dystrophy type 2.
    Finsterer J
    Eur J Neurol; 2002 Sep; 9(5):441-7. PubMed ID: 12220374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New methods for molecular diagnosis and demonstration of the (CCTG)n mutation in myotonic dystrophy type 2 (DM2).
    Sallinen R; Vihola A; Bachinski LL; Huoponen K; Haapasalo H; Hackman P; Zhang S; Sirito M; Kalimo H; Meola G; Horelli-Kuitunen N; Wessman M; Krahe R; Udd B
    Neuromuscul Disord; 2004 Apr; 14(4):274-83. PubMed ID: 15019706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does proximal myotonic myopathy show anticipation?
    Kruse B; Wöhrle D; Steinbach P; Gal A
    Hum Mutat; 2008 Aug; 29(8):E100-2. PubMed ID: 18484632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expanded [CCTG]n repetitions are not associated with abnormal methylation at the CNBP locus in myotonic dystrophy type 2 (DM2) patients.
    Santoro M; Fontana L; Maiorca F; Centofanti F; Massa R; Silvestri G; Novelli G; Botta A
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):917-924. PubMed ID: 29291944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A reversal of misfortune for myotonic dystrophy?
    Cooper TA
    N Engl J Med; 2006 Oct; 355(17):1825-7. PubMed ID: 17065646
    [No Abstract]   [Full Text] [Related]  

  • 40. [Recommendations of good practices for the genetic diagnosis of myotonic dystrophy. Grupo AEGH/CIBERER].
    Garcia Planells J; Molano J; Borrego S;
    Med Clin (Barc); 2011 Mar; 136(7):303-8. PubMed ID: 20863536
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.